Sangivamycin |
| Catalog No.GC63439 |
뉴클레오시드 유사체인 산기바마이신(NSC 65346)은 Ki가 10μM인 단백질 키나제 C(PKC)의 강력한 억제제입니다. 산기바마이신은 다양한 인간 암에 대한 강력한 항증식 활성을 가지고 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 18417-89-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Sangivamycin (NSC 65346), a nucleoside analog, is a potent inhibitor of protein kinase C (PKC) with an Ki of 10 μM. Sangivamycin has potent antiproliferative activity against a variety of human cancers[1][2].
Sangivamycin has differential antitumor effects in drug-sensitive MCF7/wild type (WT) cells, causing growth arrest, and in multidrug-resistant MCF7/adriamycin-resistant (ADR) human breast carcinoma cells, causing massive apoptotic cell death[2].Sangivamycin (0.3 μM; 0-72 hours), shows almost maximal cytocidal (for MCF7/ADR) or cytostatic (for MCF7/WT) effects[2].Sangivamycin activates caspases in MCF7/ADR cells. Upon exposure of MCF7/ADR cells to Sangivamycin (0.3 μM;), a vast amount of cleavage of lamin A to a 28-kDa fragment is detected within 48 hours[2].
[1]. Loomis CR, Bell RM. Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. J Biol Chem. 1988;263(4):1682-1692.
[2]. Lee SA, et al. The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation. J Biol Chem. 2007;282(20):15271-15283.
Average Rating: 5 (Based on Reviews and 8 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *